News

Public · Published

Zevra Therapeutics Reports Q3 2026 Revenue of $37.8M and Net Income of $19.2M

Zevra Therapeutics reported third-quarter 2026 revenue of $37.8 million, up 45% from a year earlier, and net income of $19.2 million. Diluted earnings were $0.26 per share, compared with a $0.01-per-share loss in Q3 2025. The company reported $270.9 million in cash, equivalents and investments at September 30, 2026.

Published:

Updated:

What happened

Zevra Therapeutics reported third-quarter 2026 revenue of $37.8 million, up 45% from a year earlier, and net income of $19.2 million. Diluted earnings were $0.26 per share, compared with a $0.01-per-share loss in Q3 2025. The company reported $270.9 million in cash, equivalents and investments at September 30, 2026.

Confirmed

Global impact / market context

Revenue growth and a return to reported profit could strengthen Zevra’s ability to fund operations and commercial activity without immediately relying on new financing. However, the $19.2 million net income included $5.1 million of noncash gains from liability value adjustments, so it does not all represent cash generated.

Analyst inference

MIPLYFFA generated $34.0 million of the quarter’s $37.8 million revenue, making reported sales heavily concentrated in that product. Investors may therefore focus on whether its prescriptions and revenue continue to grow; the supplied article gives 13 new enrollment forms but no complete cumulative total.

Analyst inference

What to watch

  1. Track future MIPLYFFA revenue and prescription enrollment forms: continued growth would support sales, while slower uptake could weaken the main reported source of quarterly revenue. Analyst inference
  2. Compare future net income with operating income and cash levels, since the reported quarter included $5.1 million of noncash gains from liability value adjustments. Analyst inference
  3. The article reports $270.9 million in cash, equivalents and investments at September 30, 2026; later reports can show how this balance changes as operations continue. Confirmed

Evidence

  • Original source link unavailable